Recapitalization Becomes A Better Alternative In A Weak Economy
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotechs face the new reality that recapitalization may be the only route to new funding when development plans go off track due to the constricted capital markets.
You may also be interested in...
CeNeRx Completes Series C To Fund Trial; Find Partner
The biopharma raises a third round of financing to help finish a mid-stage trial for its antidepressant TriRima.
Top Partnering Opportunities In Neuroscience: The Ugly Truth
Consultant notes some promising candidates in a challenging space for investment.
Zelos Becoms Azelon; Restructures To Close A Series A
The osteoporosis drug company has revamped its focus and brought in new investors as it pushes forward with its nasal spray for osteoporosis.